



21 May 2018

**Omega Diagnostics Group PLC  
("Omega" or "the Company" or the "Group")**

**VISITECT® CD4 development update**

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update with its VISITECT® CD4 development programme.

Further to the announcement on 10 April 2018, the Company recently held a design review meeting for its VISITECT® CD4 test for identifying advanced HIV disease\*. The Company confirms that results from feasibility testing show acceptable performance against design goals and accordingly, the Company has progressed into a formal optimisation phase within its design control programme.

**Colin King, CEO of Omega commented:** *"I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications. This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market. I look forward to making further announcements as we bring this product to market."*

*\* defined as those patients with lower than 200 CD4+ T cells per microlitre of blood*

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

**Contacts:**

**Omega Diagnostics Group PLC**

Colin King, Chief Executive

Kieron Harbinson, Group Finance Director

Tel: 01259 763 030

[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/James Thompson (Corporate Finance)

Camille Gochez/ Abigail Wayne (Corporate Broking)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus

Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)

Mob: 07980 541 893

Mob: 07584 391 303